Epigenetics and mutations in chronic myeloproliferative neoplasms.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Optimized Test Utilization Significantly Increased the Positive Detection Rate for Myeloproliferative Neoplasms.Cancers · 2026
   Article
2. International journal of molecular sciences · 2026
   Article
3. Unleashed condensation by recurrent mutations of an epigenetic regulator promotes cancer.bioRxiv : the preprint server for biology · 2026
   Article
4. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.Journal of hematology & oncology · 2019
   Article
5. Epigenetics in Myeloproliferative Neoplasms.Journal of cellular and molecular medicine · 2017
   Review
6. ASXL1 plays an important role in erythropoiesis.Scientific reports · 2016
   Article
7. A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.Blood cancer journal · 2016
   Article
8. Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.PloS one · 2015
   Article
9. Novel myelofibrosis treatment strategies: potential partners for combination therapies.Leukemia · 2014
   Review
10. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.International journal of general medicine · 2014
    Article
11. JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.JAK-STAT · 2013
    Article

Corrections and comments

• Comment on
  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as